PT-141
Bremelanotide · Vyleesi
Melanocortin agonist for desire; FDA-approved as Vyleesi.
A melanocortin receptor agonist (primarily MC4R) approved as Vyleesi for premenopausal hypoactive sexual desire disorder. Works centrally, not via nitric oxide like PDE5 inhibitors.
Usual range
0.5–1.75 mg
Schedule
As needed, ≥48 h apart (max 8×/month branded)
Half-life
~2–3 hours (effect 6–12 h)
How it is used
Melanocortin agonist for desire; FDA-approved as Vyleesi.
Subcutaneous
45–60 minutes before desired effect. Test a small dose first — nausea is common.
As needed. Branded label: no more than one dose in 24 h, eight per month.
How to mix this vial
Typical vial 10 mg · 2 mL BAC
Branded Vyleesi is 1.75 mg autoinjector. Compounded 10 mg + 2 mL → 5 mg/mL. 1 mg = 20 units.
Fridge for compounded; branded autoinjectors follow label.
Side effects
- Nausea (very common)
- Flushing
- Headache
- Darkening of gums/skin with repeated use
- Blood pressure changes
Who should skip this
- Uncontrolled hypertension
- Cardiovascular disease
- Pregnancy
Nutrition note
Take on a lighter stomach. Ginger may help nausea. Alcohol worsens it.
Vyleesi 1.75 mg is the approved female HSDD dose. Men in research settings often start lower because of nausea. Compounded PT-141 is not Vyleesi.
Peptipedia is an educational calculator, not medical advice. Many catalog entries are unapproved for human use. Approved molecules have labels that outrank this app. Do not use this to self-prescribe. Consult a licensed clinician. Not for anyone under 18, pregnant, or being treated for cancer.